Software & App
Solutions

Estima has developed a web-based app (EST) for connected networks and a desktop app for population adjusted analyses, disconnected networks and single arm trials, which are being used by Top 10 Pharma companies both for early HTA planning and directly in HTA submissions.

A combination of our technology products and consulting services helps pharmaceutical companies and biotechs use network meta-analysis (NMA), matching-adjusted indirect comparisons (MAIC), and simulated treatment comparisons (STC) more effectively through technology to guide early decision making and clinical development:

— to conduct early feasibility analysis and NMAs.
— to put the results into early economic models to determine economically justifiable prices (EJPs) and/or the probability of being cost effective at HTA.

Estima has developed a web-based app to conduct automated end-to-end SLRs using Gen AI:

— Searching PubMed.
— Screening title, abstracts and full-text screening at unprecedented speed, processing up to 10,000 abstracts in just 10 minutes.
— Full tracking of results included and excluded at each stage with reason for exclusion.
— Fully interactive to allow human intervention to review and override AI decisions.
— Production of report results PRISMA.

In our recent study, we found that screening sensitivity and specificity of title and abstract screening by GPT-4 was 95.9% and 86.7% respectively; and 97.1% and 66.1% respectively after full text review.

We are currently working towards implementing further automated solutions for SLRs, NMAs and economic modelling.